Conversion of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 to manifest ataxia (RISCA): a longitudinal cohort study
- Heike Jacobi
- Sophie Tezenas du Montcel
- Sandro Romanzetti
- Florian Harmuth
- Caterina Mariotti
- Lorenzo Nanetti
- Maria Rakowicz
- Grzegorz Makowicz
- Alexandra Durr
- Marie-Lorraine Monin
- Alessandro Filla
- Alessandro Roca
- Ludger Schöls
- Holger Hengel
- Jon Infante
- Jun-Suk Kang
- Dagmar Timmann
- Carlo Casali
- Marcella Masciullo
- Laszlo Baliko
- Bela Melegh
- Wolfgang Nachbauer
- Katrin Bürk-Gergs
- Jörg B Schulz
- Olaf Riess
- Kathrin Reetz
- Thomas Klockgether
Description
In this prospective, longitudinal, observational cohort study, based at 14 referral centres in seven European countries, we enrolled children or siblings of patients with SCA1, SCA2, SCA3, or SCA6. Eligible individuals were those without ataxia, defined by a score on the Scale for the Assessment and Rating of Ataxia (SARA) of less than 3; participants had to be aged 18-50 years for children or siblings of patients with SCA1, SCA2, or SCA3, and 35-70 years for children or siblings of patients with SCA6. Study visits took place at recruitment and after 2, 4, and 6 years (plus or minus 3 months). We did genetic testing to identify mutation carriers, with results concealed to the participant and clinical investigator. We assessed patients with clinical scales, questionnaires of patient-reported outcome measures, a rating of the examiner's confidence of presence of ataxia, and performance-based coordination tests. Conversion to ataxia was defined by an SARA score of 3 or higher. We analysed the association of factors at baseline with conversion to ataxia and the evolution of outcome parameters on temporal scales (time from inclusion and time to predicted age at ataxia onset) in the context of mutation status and conversion status. This study is registered with ClinicalTrials.gov, NCT01037777.